Aytu BioPharma posts record Q1 revenue of $27.7M, first positive adjusted EBITDA of $1.4M

AYTU BIOPHARMA, INC

2023-Q1 EPS reported -$0.06 revenue$27,655,000

Record quarterly net revenue of $27.7M, up 26% YoY; Rx segment revenue grew 34% to $18.7M.
Positive adjusted EBITDA of $1.4M vs. ($4.2M) loss a year ago; net loss narrowed to ($2.9M).
Indefinitely suspended clinical programs (AR101/enzastaurin), saving over $20M in future study costs.
Leadership changes: Jarrett Disbrow as Chief Business Officer, Topher Brooke as COO, Ryan Selhorn as EVP Finance.
Extended interest-only period on Avenue debt to Jan 2024, saving $3M in 2023 principal payments; warrant exercise price reset to $0.43.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

AYTU BIOPHARMA, INC reported the first quarter of fiscal year 2023 ended September 30, 2022 results: revenue $27.7 million.

Period: the first quarter of fiscal year 2023 ended September 30, 2022
Revenue: $27.7 million
Result: reported results

Exact text from the filing

Q1 2023 Commercial Highlights (3 months ending September 30, 2022) · Total net revenue was $27.7 million, a new quarterly record, and an increase of 26% over the $21.9 million in net revenue in the year ago quarter.

View on SEC.gov

Browse all earnings releases →

AYTU BIOPHARMA, INC filing history →

Source: SEC EDGAR

accession 0001558370-22-017765

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.